# Cenduit

> Cenduit is a clinical trial technology and services business now operating as IQVIA IRT. Its randomization and trial supply management systems help biopharmaceutical sponsors, CROs, and research sites assign treatments, manage investigational medicine, and adapt operations as studies change.

- **Founded:** 2007
- **Headquarters:** Durham, United States
- **Founders:** Quintiles Transnational Corp. (Corporate joint-venture co-founder), Thermo Fisher Scientific Inc. (Corporate joint-venture co-founder)
- **Products:** IQVIA IRT (formerly Cenduit), Quantum Interactive, Supply Automation Value Engine (SAVE), Mobile IP, Material forecasting dashboard
- **Notable:** A published oncology rescue case reports a mid-study system transition while maintaining the original schedule., Selected SAVE case studies report annual drug and shipping savings between US$150,000 and US$1 million; outcomes are case-specific., The 2026 IQVIA IRT fact sheet reports a library of more than 140 pre-validated components.

## Products & services

- **IQVIA IRT (formerly Cenduit)** — Cloud-based randomization and trial supply management, with study configuration, validation, and ongoing delivery support.
- **Quantum Interactive** — Study design and prototyping tool demonstrated publicly in 2017 and 2018.
- **Supply Automation Value Engine (SAVE)** — Evaluates supply conditions to adjust resupply strategies and reduce inventory and shipping waste.
- **Mobile IP** — Mobile investigational-product accountability and collaboration for site staff and monitors.
- **Material forecasting dashboard** — Tools for forecasting study supply needs and managing depot stock.
- **Early phase IRT configuration** — Self-service management of changing cohorts, treatment arms, visits, sites, and users, described in August 2025.
- **Drug Supply Center of Excellence** — Specialist clinical supply consultation, study-specific strategies, and delivery expertise.
- **Integration and global support** — Clinical-system connections and multilingual 24-hour support for trial operations.

## Achievements

- A published oncology rescue case reports a mid-study system transition while maintaining the original schedule.
- Selected SAVE case studies report annual drug and shipping savings between US$150,000 and US$1 million; outcomes are case-specific.
- The 2026 IQVIA IRT fact sheet reports a library of more than 140 pre-validated components.

## Latest updates

- **2026-06** — IQVIA published an IRT supply-chain article on predictive forecasting, continuous resupply optimization, and integration.
- **2026-04** — Updated IQVIA IRT fact sheet describes cloud-based RTSM, Mobile IP, SAVE, forecasting, and delivery services.
- **2025-08** — IQVIA described self-service IRT tools tailored to early phase trials.
- **2025-07** — IQVIA quality assurance published guidance on IRT inspection readiness.
- **2025-05** — IQVIA published an article on IRT for cell and gene therapy trials.

## Links

- Website: https://www.cenduit.com
- LinkedIn: https://www.linkedin.com/company/cenduit
- Twitter/X: https://twitter.com/CenduitLLC
- Facebook: https://facebook.com/pages/Cenduit/135244346594125

---

Profile page: https://yespress.io/cenduit
Published by YesPress — https://yespress.io
Last updated: 2026-10-02